Human CellExp™ NOV, human recombinant | P1022

Nephroblastoma Overexpressed Gene Protein (NOV), also known as CCN3, IGFBP9 and NOVH, is one of the CCN family of secreted proteins. It is expressed in bone marrow, thymic cells and nephroblastoma. NOV signals through integrin receptors, NOTCH1 and fibulin 1c to regulate multiple cellular activities, such as cell adhesion, migration, proliferation and differentiation. The reported functions of NOV are diverse. It has been reported to play a role in angiogenesis and stem cell self-renewal. It has also been implicated in osteogenic differentiation, embryo development and cancer pathogenesis.

P1022 | Human CellExp NOV human recombinant DataSheet

Biomolecule/Target: NOV

Synonyms: Nephroblastoma Overexpressed gene, CCN3, IGFBP9, NovH

Alternates names: Fms-like tyrosine kinase 1, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Vascular permeability factor receptor

Taglines: N/A

NCBI Gene ID #: 2321

NCBI Gene Symbol: FLT1

Gene Source: Human

Accession #: P17948

Recombinant: Yes

Source: Insect cells

Purity by SDS-PAGEs: 90%

Assay: SDS-PAGE

Purity: > 95%

Assay #2: HPLC

Endotoxin Level: < 0.2 EU/g

Activity (Specifications/test method): N/A

Biological activity: Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 µg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml.

Results: 8-500 ng/ml.

Binding Capacity: N/A

Unit Definition: N/A

Molecular Weight: 96 kDa

Concentration: N/A

Appearance: Lyophilized

Physical form description: Lyophilized after extensive dialysis against PBS.

Reconstitution Instructions: Reconstitute in water to a concentration not less than 0.1 mg/ml. This solution can then be stored at 4°C for 2-7 days. For future use for future use; For long term storage it is recommended to add a carrier protein (0.1 % HSA or BSA) then store at –20°C. Avoid freeze-thaw cycles.

Amino acid sequence: MVSYWDTGVL LCALLSCLLL TGSSSGSKLK DPELSLKGTQ HIMQAGQTLH LQCRGEAAHK WSLPEMVSKE SERLSITKSA CGRNGKQFCS TLTLNTAQAN HTGFYSCKYL AVPTSKKKET ESAIYIFISD TGRPFVEMYS EIPEIIHMTE GRELVIPCRV TSPNITVTLK KFPLDTLIPD GKRIIWDSRK GFIISNATYK EIGLLTCEAT VNGHLYKTNY LTHRQTNTII DVQISTPRPV KLLRGHTLVL NCTATTPLNT RVQMTWSYPD EKNKRASVRR RIDQSNSHAN IFYSVLTIDK MQNKDKGLYT CRVRSGPSFK SVNTSVHIYD KAFITVKHRK QQVLETVAGK RSYRLSMKVK AFPSPEVVWL KDGLPATEKS ARYLTRGYSL IIKDVTEEDA GNYTILLSIK QSNVFKNLTA TLIVNVKPQI YEKAVSSFPD PALYPLGSRQ ILTCTAYGIP QPTIKWFWHP CNHNHSEARC DFCSNNEESF ILDADSNMGN RIESITQRMA IIEGKNKMAS TLVVADSRIS GIYICIASNK VGTVGRNISF YITDVPNGFH VNLEKMPTEG EDLKLSCTVN KFLYRDVTWI LLRTVNNRTM HYSISKQKMA ITKEHSITLN LTIMNVSLQD SGTYACRARN VYTGEEILQK KEITIRGEHC NKKAVFSRIS KFKSTRNDCT TQSNVKH